MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Afuresertib hydrochloride

CAS No. : 1047645-82-8

MCE 站：Afuresertib hydrochloride

产品活性：Afuresertib hydrochloride (GSK 2110183 hydrochloride) 是一个口服有效的，ATP 竞争性的选择性 pan-Akt 抑制剂，作用于 Akt1/Akt2/Akt3，K_i 值分别为 0.08/2/2.6 nM。

研究领域：PI3K/Akt/mTOR  |  TGF-beta/Smad  |  Epigenetics  |  Stem Cell/Wnt  |  Cytoskeleton  |  Cell Cycle/DNA Damage

作用靶点：Akt  |  PKC  |  ROCK

In Vitro: Afuresertib (GSK 2110183) exhibits favorable tumor-suppressive effects on malignant pleural mesothelioma (MPM) cells. Afuresertib significantly increases caspase-3 and caspase-7 activities and apoptotic cell number among ACC-MESO-4 and MSTO-211H cells. Afuresertib strongly arrests the cell cycle in the G₁ phase.
Western blotting analysis shows that Afuresertib increases the expression of p21^WAF1/CIP1 and decreases the phosphorylation of Akt substrates, including GSK-3β and FOXO family proteins. Afuresertib-induced p21 expression promotes G₁ phase arrest by inducing FOXO activity. Afuresertib significantly enhances cisplatin-induced cytotoxicity. Afuresertib modulates the expression E2F1 and MYC, which are associated with fibroblast core serum response.

In Vivo: Mice bearing BT474 breast tumor xenografts are dosed orally with either vehicle or GSK2110183 at 10, 30 or 100 mg/kg daily for 21 days which result in 8, 37 and 61% TGI, respectively. Mice tolerated GSK2110183 well, with 1-3% body weight loss reported after 5 days of dosing which recover over the course of the study. Other tumor xenograft models which possess an activation of the Akt pathway are explored to further demonstrate compound efficacy. Mice treated with GSK2110183 at 10, 30 and 100 mg/kg result in 23, 37 and 97% TGI, respectively, of SKOV3 xenografts.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Epigenetics Compound Library  |  Kinase Inhibitor Library  |  PI3K/Akt/mTOR Compound Library  |  Stem Cell Signaling Compound Library  |  TGF-beta/Smad Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Glycolysis Compound Library  |  Cytoskeleton Compound Library  |  Orally Active Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Phorbol 12-myristate 13-acetate  |  Y-27632 dihydrochloride  |  Staurosporine  |  Ionomycin  |  Chroman 1  |  Go 6983  |  Midostaurin  |  Honokiol  |  Bisindolylmaleimide I  |  Fasudil Hydrochloride  |  Mitoxantrone  |  GSK-690693  |  Artemisinin  |  Oridonin  |  Perifosine  |  Rottlerin  |  Guggulsterone  |  Enzastaurin  |  Miransertib  |  Narciclasine  |  Ripasudil  |  Chelerythrine chloride  |  Ingenol Mebutate  |  Triciribine  |  Recilisib  |  SU6656  |  Ro 31-8220 mesylate  |  Isobavachalcone  |  Scutellarin

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。